Ipsen

Graphic image of a pen signing a signature while two strangelooking business people cheer

Ipsen taps Biomunex's MAITs to treat solid tumors in $610M bet

The biobuck bet has landed the French drugmaker exclusive global rights to a preclinical Biomunex prospect that engages a subset of cytotoxic T cells.

Nick Paul Taylor Dec 3, 2024 6:00am

Graphic of two hands shaking under a red and purple light

Ipsen scores 2nd ADC via $1B biobucks pact with Foreseen

Jul 11, 2024 8:14am

Ipsen, Marengo ink $1.2B biobuck deal to treat cold tumors

Jun 7, 2024 9:15am

BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

May 3, 2024 8:30am

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

Apr 22, 2024 7:01am

Ipsen posts mixed liver disease data on Intercept, CymaBay rival

Nov 14, 2023 5:55am